Functional and Clinical Impact of CYP3A Genetic Polymorphisms on Statin Therapy
NCT ID: NCT01867203
Last Updated: 2021-03-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
OBSERVATIONAL
2017-08-01
2019-09-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Genetic Influence on Statin Pharmacodynamics
NCT01569854
Lipid-lowering Therapy Individualization
NCT03604471
Fenofibrate and Pharmacogenetic Impact in Dyslipidemia
NCT00613613
The Role of P-glycoprotein in Sitagliptin Clinical Pharmacology
NCT01112670
Percentage of Secondary Prevention Patients Treated to Their LDL-C Targets
NCT00536796
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Statin users
Genotyping
DNA extraction from blood
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Genotyping
DNA extraction from blood
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age \[25-80\]
* treated with Atorvastatin, simvastatin, fluvastatin.
Exclusion Criteria
25 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Saint-Luc Hospital
Brussels, , Belgium
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CYPstatin001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.